{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:19:15Z","timestamp":1788517155553,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008211","name":"Association France Parkinson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.parkreldis.2026.108406","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:40:35Z","timestamp":1782949235000},"page":"108406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adverse event trajectories and treatment discontinuation in advanced Parkinson's disease treated with levodopa\/carbidopa intestinal gel"],"prefix":"10.1016","volume":"150","author":[{"given":"Sabrine","family":"Othmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Pinhero","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brefel-Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeineb","family":"Ennaifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Harroch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Acket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory-Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-592X","authenticated-orcid":false,"given":"Margherita","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.parkreldis.2026.108406_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108406_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-140456","article-title":"Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced parkinson's disease patients","volume":"5","author":"Slevin","year":"2015","journal-title":"J. Parkinsons Dis."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.108406_bib3","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1111\/ene.15386","article-title":"European academy of neurology\/movement disorder society - European section guideline on the treatment of parkinson's disease: I. Invasive therapies","volume":"29","author":"Deuschl","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2026.108406_bib4","article-title":"Long-Term effectiveness and safety of LCIG in Romania. 3-year results from a prospective, observational Study (DUOGLOBE)","volume":"22","author":"Szasz","year":"2026","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.parkreldis.2026.108406_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","article-title":"Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced parkinson's disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs","volume":"29","author":"P\u00e5lhagen","year":"2016","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108406_bib6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s40120-025-00766-2","article-title":"Levodopa intestinal gel infusion therapies in advanced parkinson's disease: a Swedish study on real-world use and costs","volume":"14","author":"Odin","year":"2025","journal-title":"Neurol Ther"},{"issue":"5\u20136","key":"10.1016\/j.parkreldis.2026.108406_bib7","first-page":"159","article-title":"Living alone is associated with discontinuation of levodopa-entacapone-carbidopa intestinal gel treatment in advanced parkinson's disease","volume":"88","author":"Viljaharju","year":"2025","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.parkreldis.2026.108406_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.02.020","article-title":"Antonini A and multicentre, ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP. Which patients discontinue? Issues on levodopa\/Carbidopa intestinal gel treatment: italian survey of 905 patients with long-term follow-up","volume":"38","author":"Sensi","year":"2017","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2026.108406_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2019.10.004","article-title":"Beyond 10 years of levodopa intestinal infusion experience: analysis of mortality and its predictors","volume":"76","author":"Artusi","year":"2020","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108406_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40263-016-0336-5","article-title":"Levodopa-carbidopa intestinal gel in patients with parkinson's disease: a systematic review","volume":"30","author":"Wirdefeldt","year":"2016","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108406_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/cjn.2021.78","article-title":"Vitamins and infusion of levodopa-carbidopa intestinal gel","volume":"49","author":"Taher","year":"2022","journal-title":"Can. J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108406_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mdc3.12688","article-title":"Levodopa-induced neuropathy: a systematic review","volume":"6","author":"Romagnolo","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108406_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/ene.13844","article-title":"Levodopa\/Carbidopa intestinal gel infusion and weight loss in parkinson's disease","volume":"26","author":"Fabbri","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108406_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108406_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JPD-225105","article-title":"Levodopa carbidopa intestinal gel in advanced parkinson's disease: DUOGLOBE final 3-Year results","volume":"13","author":"Chaudhuri","year":"2023","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108406_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/mds.28596","article-title":"Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study","volume":"36","author":"Fasano","year":"2021","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108406_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1468-1331.2012.03679.x","article-title":"Levodopa\/Carbidopa intestinal gel infusion long-term therapy in advanced parkinson's disease","volume":"19","author":"Nyholm","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108406_bib18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","article-title":"Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced parkinson disease: the Barcelona registry","volume":"21","author":"Buongiorno","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2026.108406_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","article-title":"GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced. Final results of the GLORIA registry","volume":"45","author":"Antonini","year":"2017","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108406_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3233\/JPD-201978","article-title":"Predictors of time to discontinuation of levodopa-carbidopa intestinal gel infusion: a retrospective cohort study","volume":"10","author":"Moes","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.parkreldis.2026.108406_bib21","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1007\/s00415-022-11269-7","article-title":"Long-term safety, discontinuation and mortality in an Italian cohort with advanced parkinson's disease on levodopa\/carbidopa intestinal gel infusion","volume":"269","author":"Garr\u00ec","year":"2022","journal-title":"J. Neurol."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026002336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026002336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:05:59Z","timestamp":1788516359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802026002336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"alternative-id":["S1353802026002336"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108406","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse event trajectories and treatment discontinuation in advanced Parkinson's disease treated with levodopa\/carbidopa intestinal gel","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108406"}}